Tags |
|
|
Links |
|
|
Top Articles - Spot Uranium Price Trapped at $72/Pound
According to the January 26th edition of Nuclear Market Review (NMR), the spot uranium price hasn’t budged for a sixth straight week – the longes
According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
t period of no price change since June 2005. NMR again reported no change in either the spot or long-term uranium price indicator, which remains
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.
Examples of combination products may in
Examples of combination products may in
respectively at $72 and $69/pound. TradeTech is the first to post the weekly spot uranium price indicator on the consulting company’s website.
T
T
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
he good news for uranium mining companies, and especially their share prices, is that the spot uranium price has steadfastly remained above US$60
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
/pound for three straight months. This may be a secure production cost pricing point to give many of the upcoming uranium projects a comfortable
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
Combination pro
profit cushion. But how long will the price remain frozen at this level?
NMR editor Treva Klingbiel wrote, “The gap that previously existed betw
NMR editor Treva Klingbiel wrote, “The gap that previously existed betw
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
een willing buyers and willing sellers has widened dramatically, and as a result, buyers and sellers are finding it increasingly difficult to fin
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
common ground with many transactions failing to reach conclusion.”
The impasse between buyers and sellers could continue for a while longer. NR
The impasse between buyers and sellers could continue for a while longer. NR
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
M reported that nine buyers are seeking offers for approximately 4.4 million pounds of U3O8 equivalent. Klingbiel observed, “About one-half of th
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
is quantity is discretionary.”
NMR wrote the stalemate may not break “until the market regains momentum.” Klingbiel cited “the holiday season an
NMR wrote the stalemate may not break “until the market regains momentum.” Klingbiel cited “the holiday season an
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
d routine year-end quietness” for the stalemate. But she also wrote, “The greatest factor, however, is the dramatic jump in price that occurred o
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
Following aspects would a
n December 15th.” That was when TradeTech’s Weekly Spot Uranium Price Indicated jumped a record $7/pound to $72/pound.
On Thursday, Cameco Corp
On Thursday, Cameco Corp
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
Which markets to tap where the combination products can do fairly well?
Which combination prod
issued an update on the company’s Cigar Lake uranium project, explaining that the company hopes to seal off the water inflow sometime in the seco
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
nd quarter. An update about remediation capital costs and timelines was expected in February, but Cameco won’t have a report ready until March. O
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
Monday, rumors were flying about Cameco’s Cigar Lake project, which led to the biggest single-day drop in the company’s share price since the ur
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
anium mine flooding was announced.
Supply may remain tight coming into 2007. Australia’s two largest uranium mining operations, BHP Billiton’s O
Supply may remain tight coming into 2007. Australia’s two largest uranium mining operations, BHP Billiton’s O
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
Professional from academic institutions, pharmaceutical industries, health care indust
lympic Dam and ERA’s Ranger, both reported 20-percent or greater production drops for 2006. For the time being, it should be noted that hardly an
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
y uranium mining stock, whose development prospects are on the horizon, has suffered because of the spot uranium price deep freeze.
By the way,
By the way,
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
after the spot uranium price hovered around the $30/pound level during the summer of 2005, it began its momentous rally which attracted both new
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
Companies that provide selfless information through particip
issuers and investors to the uranium bull market party. If history repeats itself…
COPYRIGHT (C) 2007 by StockInterview, Inc. ALL RIGHTS RESERVE
COPYRIGHT (C) 2007 by StockInterview, Inc. ALL RIGHTS RESERVE
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.toparticles.org.ua/article/102310/toparticles-Spot-Uranium-Price-Trapped-at-72Pound.html">Spot Uranium Price Trapped at $72/Pound</a>
BB link (for phorums):
[url=http://www.toparticles.org.ua/article/102310/toparticles-Spot-Uranium-Price-Trapped-at-72Pound.html]Spot Uranium Price Trapped at $72/Pound[/url]
Related Articles:
5 Steps to Fantastic Success With Resale Rights Products
E-Commerce Women Are Different Breeds That E-Commerce Men
Why Your Web Designer Should Know About Web Marketing
Bookmark it:
|